Research article · 18 Aug 2015
Conference abstractPublished 5 Oct 2018
Immune report card
OmniSeq, USA; Roswell Park Comprehensive Cancer Center, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Immune report card is a New York State CLEP approved assay and is designed to provide comprehensive factual information for clinicians to support the decision process around the use of immuno-therapeutics with an emphasis on CPIs. IRC provides this information by analyzing the host immune response and multiple immunotherapy biomarkers using several testing modes and integrates the results into a single report. Specifically, IRC uses five test modes (1) RNA-seq to semi-quantitatively measure transcript levels of 384 immune response (IR) genes. (2) DNA-seq to estimate mutational burden. (3) MSI-PCR to assess microsatellite instability. (4) Fluorescent in situ Hybridization (FISH) to detect copy number gain of PD-L1 and PD-L2. (5) Immunohistochemistry (IHC) to measure protein expression of PD-L1 in the context of an FDA-approved assay and also to provide the pattern of expression for this marker as well as for CD3 and CD8. To summarize, from a clinical perspective the evaluation of TCRS, TILS, MuB, MSI and PD-L1/2 copy number provide comprehensive results for physician decision making regarding potential response to checkpoint inhibition therapy in a single report. IRC provides the most complete profile of the cell-mediated immune response and potential antigens to drugs targeting the PD-1 and PD-L1 pathway by consolidating results of drug-target gene expression, immune cell infiltration, MSI and mutation burden into a single harmonized report available today.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 27 Aug 2014
Genetic addiction risk score (GARSrx), comprehensive analysis of reported drugs (CARD) dopamine agonist therapy (kb220z): Embracing genetic prediction of addiction risk severity for pain and addiction treatment
Conference abstract · 27 Aug 2014
Genetic addiction risk score (GARSrx), comprehensive analysis of reported drugs (CARD) dopamine agonist therapy (kb220z): Embracing genetic prediction of addiction risk severity for pain and addiction treatment
Conference abstract · 22 Jun 2013
Genetic Addiction Risk Scores (GARS) coupled with the Comprehensive Analysis of Reported Drugs (CARD) provide diagnostic and outcome data supporting the need for dopamine D2 agonist therapy: Proposing a holistic -therapeutic model for Reward Deficiency Syndrome (RDS)
Editorial · 2013
Clinical Practices that can Combat Endemic Legal Opioid Dependence: Genetic Addiction Risk Score (GARS) TM , KB220Z TM , Comprehensive Analysis of Reported Drugs (CARD) and Electrotherapy
More from this journal
The newest in Journal of Women's Health Care.
Short communication · 29 Sep 2025
Advancing Women’s Health Through Cervical Cancer Screening
Short communication · 29 Sep 2025
Menopause Management: Enhancing Quality of Life for Women
Mini review · 29 Sep 2025
Breast Health: A Vital Aspect of Women’s Well-Being
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Women's Health Care
- SubjectNursing & Healthcare
- SubjectReproductive Medicine & Gynaecology
- BylineArticles whose byline prints “Carl Morrisson”

